These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35383486)

  • 21. Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance.
    Choi HH; Kim S; Shum DJ; Huang CY; Shui A; Fox RK; Khalili M
    Radiol Imaging Cancer; 2024 Jan; 6(1):e230118. PubMed ID: 38214600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C-Triggered Abbreviated MRI.
    Mulgaonkar A; Huang DQ; Siddiqi H; Fowler K; Sirlin CB; Marks R; Loomba R; Konijeti GG
    Am J Gastroenterol; 2024 Jul; 119(7):1326-1336. PubMed ID: 38146873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
    Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
    Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
    Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
    AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
    [No Abstract]   [Full Text] [Related]  

  • 28. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma.
    Fetzer DT; Rodgers SK; Seow JH; Dawkins AA; Joshi G; Gabriel H; Kamaya A
    Radiol Clin North Am; 2019 May; 57(3):563-583. PubMed ID: 30928078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interobserver Agreement Between Primary Sonographers and Secondary Overreaders for Screening and Surveillance Liver Ultrasounds Using Ultrasound Liver Imaging Reporting and Data System.
    Dawkins A; Nelson LW; Gulati V; Stepp A; Chapelin F; Khurana A
    Ultrasound Q; 2022 Jun; 38(2):116-123. PubMed ID: 35678479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System.
    Fetzer DT; Rodgers SK; Harris AC; Kono Y; Wasnik AP; Kamaya A; Sirlin C
    Radiol Clin North Am; 2017 Nov; 55(6):1197-1209. PubMed ID: 28991560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.
    Darnell A; Forner A; Rimola J; Reig M; García-Criado Á; Ayuso C; Bruix J
    Radiology; 2015 Jun; 275(3):698-707. PubMed ID: 25658038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol.
    da Silva PH; Gomes MM; de Matos CAL; de Souza E Silva IS; Gonzalez AM; Torres US; Salazar GMM; D'Ippolito G
    J Ultrasound Med; 2021 Nov; 40(11):2487-2495. PubMed ID: 33463734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality Assessment of Ultrasound and Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis.
    Quek J; Tan DJH; Chan KE; Lim WH; Ng CH; Ren YP; Koh TK; Teh R; Xiao J; Fu C; Syn N; Teng M; Muthiah M; Fowler KJ; Sirlin CB; Loomba R; Huang DQ
    Dig Dis; 2023; 41(5):757-766. PubMed ID: 37231918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.